Morphological bottlenecks of static protein and RNA guides and the genetic toxicity blind spot of RNA targeting Artificial manipulation of the cellular transcriptome and clearance of pathogenic mRNAs constitute a central challenge in molecular medicine. However, existing RNA‑guide‑based systems such as Cas13 or protein‑induced targeting constructs have suffered from complex three‑dimensional constraints and the intrinsically short half‑life of guide RNAs in cells, leading to a steep decline in transcript correction efficiency. Moreover, conventional guide modalities induce off‑target transcript perturbation, cytotoxic noise, and require intricate backbone design guidelines, representing a long‑standing technical bottleneck and a molecular‑biological blind spot that hampers high‑throughput functional genomics and the development of safe RNA inhibitors.

DNA‑guided CRISPR‑Cas12a implementation: native heteronucleic acid hybrid docking mechanism In the study published in Nature Biotechnology on 26 May, we reset the guide‑structure paradigm by fully deploying a DNA‑guided CRISPR–Cas12a effector architecture. The team chemically remodeled the catalytic core of Cas12a—previously known to cleave only DNA—to accommodate an artificially synthesized single‑stranded DNA (ssDNA) guide backbone. When the guide DNA hybridizes with a target RNA sequence, a stable DNA‑RNA R‑loop topology forms, triggering a conformational change in the Cas12a complex that enables single‑nucleotide‑resolution recognition and cleavage of the target transcript, thereby demonstrating for the first time a heteronucleic‑acid‑induced mechanism.

Ultra‑sensitive target transcript inactivation and elimination of off‑target transcript contamination Kinetic analyses in vitro demonstrated that the DNA‑guide‑Cas12a complex achieved markedly higher turnover rates and catalytic cleavage efficiencies against a panel of disease‑associated human RNA targets compared with conventional RNA‑guide systems. The thermodynamic stability of the synthetic DNA guide provided prolonged protection against intracellular nuclease attack, and stringent mismatch discrimination suppressed off‑target transcript cleavage to baseline levels. This engineering fidelity proves an overwhelming computational‑genetic “trench” that selectively filters disease transcripts without inducing permanent double‑strand breaks.

Establishment of next‑generation RNA precision‑medicine standards and formalization of an in‑silico nucleic‑acid design platform The structural‑biology and programmable nucleic‑acid engineering dataset generated herein delivers a disruptive impact on the global next‑generation biopharma R&D sector and programmable nucleic‑acid therapeutic business. By shifting RNA‑editing therapeutic specifications from simple RNA‑backbone substitution to a low‑cost, highly stable, mass‑producible artificial DNA‑guide plug‑in architecture, we provide a new benchmark. The derived DNA‑RNA binding free‑energy tensor enables computational engines to calculate secondary‑structure barriers of target transcripts and virtually synthesize optimal oligonucleotide sequences, establishing a standard for simulation‑based design. This resource eliminates false‑positive resistance arising from guide degradation in clinical pipelines and serves as a master reference that can exponentially shorten IND approval timelines for next‑generation antisense‑based gene‑editing modalities with regulatory agencies.